RE:RE:RE:RE:Q3 Report...Very Good but US not soCPH traded in the $15 range in 2015, on its very strong cash flowing canadian assets.
Subequent to the April 2015 acqusition of its US assets, it share price has progressively traded downwards.
It was stated at the time that the US asset would become accretive in 2017.
That may yet happen, but they have a lot of work to do yet.
Should they sell the US assets, CPH would once again rise above $10.
This is my ideal outcome, as they wont get as much for a sale as they would from the market.
Insiders own a whack of shares, so perhaps they may concentrate on selling the US assets while continueing to advance their strong Canadian assets which have several more drugs entering the revenue streams in 2017